Peritoneal dialysis fluid (lactate)

Peritoneal dialysis uses the peritoneum as a semipermeable membrane. Water and solutes are exchanged between the peritoneal capillaries and the dialysate. Electrolytes and small molecules move from the high concentration side to the low concentration side (diffusion), while water molecules move from the low osmotic concentration side to the high osmotic concentration side (osmosis). Increasing the dialysate concentration can achieve the purpose of removing water from the body. Through the solute concentration gradient difference, uremic substances in the blood can be removed from the dialysate, and electrolyte and acid-base balance can be maintained, replacing part of the kidney's function. The basic principles of peritoneal dialysis fluid formulation: (1) The water used for the dialysate must be strictly sterile and endotoxin-free. (2) The electrolyte concentration of the dialysate is close to that of normal plasma and can be adjusted according to clinical conditions. In this dialysate: ① The sodium ion concentration is 132mmol/L, slightly lower than positive.

This product is a compound preparation.

Replenish heat energy and body fluids. Used for insufficient food intake or large amount of body fluid loss caused by various reasons.

For the treatment of acute and chronic renal failure with water retention, intermittent peritoneal dialysis is used, 2L each time, retained for 1 to 2 hours, and exchanged 4 to 6 times a day. For those without water retention, continuous ambulatory peritoneal dialysis (CAPD) is used, generally 4 times a day, 2L each time, with an interval of 4 to 5 hours during the day and 9 to 12 hours at night, to increase the clearance of middle molecular uremic toxins. The average daily dialysate volume is 8L.

Common adverse reactions of peritoneal dialysis fluid include: 1. Dehydration 2. Hypokalemia 3. Hyperglycemia 4. Hyponatremia, hypochloremia, metabolic alkalosis 5. Chemical peritonitis.

1. It is contraindicated for patients with brain, kidney and heart dysfunction; 2. It is contraindicated for patients with low plasma protein; 3. It is contraindicated for patients with uncontrolled diabetes and ketoacidosis; 4. It is contraindicated for patients with hyperosmotic dehydration; 5. It is contraindicated for patients with hyperglycemia and non-diabetic hyperosmotic state.

Not yet clear.

Keep away from light and store in a sealed container.

1.5% glucose: 1500ml

Huaren Pharmaceutical Co., Ltd.

• Founded in:

  1998-05-20

• Address:

  No. 187, Zhuzhou Road, Qingdao High-tech Industrial Park

• Tax NO.:

  91370200706426601X

• Registered Funds:

  1,182,212,982 yuan

• Website:

  Log in to view

• Email:

  Log in to view